Q-omics provides the consensus-scored BTG1P1 profile across patient tissues and cancer cell-line models. BTG1P1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, BTG1P1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, BTG1P1 RNA expression shows 17,735 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where BTG1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTG1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTG1P1 survival associations across molecular data types. BTG1P1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTG1P1 RNA expression–survival associations across cancer types. High BTG1P1 expression shows unfavorable associations in LUAD, but favorable associations in HNSC, PAAD, BRCA, SKCM and KICH. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for BTG1P1 RNA expression.
This table summarizes BTG1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BTG1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTG1P1 shows lower tumor expression in LUSC, BLCA, KICH, LUAD and THCA and higher tumor expression in KIRC. The KIRC box plot shows higher BTG1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.291, t-test p < 0.001).
This table shows molecular features associated with BTG1P1 in patient tissues and cancer cell lines. In patient samples, BTG1P1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
